Opportunity
Simpler Grants.gov #RFA-DK-28-213
Clinical research centers for gastrointestinal interoception and motility disorders
Buyer
National Institutes of Health (NIH)
Posted
November 03, 2026
Respond By
March 05, 2027
Identifier
RFA-DK-28-213
NAICS
541715
The National Institutes of Health is seeking clinical research centers to study gastrointestinal interoception and related motility disorders. - Government buyer: U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Division of Digestive Diseases and Nutrition. - Opportunity: Up to six Clinical Research Centers for the Diseases of Gastrointestinal Interoception Consortium (DGIC), supported through a U01 cooperative agreement. - Requested services: Conduct clinical research on gastrointestinal interoception, symptoms, and motility disorders; recruit participants; perform clinical assessments and collect biospecimens under consortium protocols; and collaborate with other research centers and the Scientific Data Research Center. - Research interests: Mechanisms linking interoception, symptoms, and motility; biomarkers; gut-brain signaling; microbiome relationships; and potential targets for future treatment research. - Funding and duration: NIDDK anticipates $4.5 million in total funding for up to six awards. Applications are capped at $500,000 in direct costs per year, with projects lasting up to five years. - Important requirement: Clinical trials are not allowed. Applicants must demonstrate patient recruitment capability and participate in consortium-wide protocols and collaboration. - OEMs and vendors: None are identified; this is a research-services opportunity, not a product purchase.
Description
This funding opportunity invites new applications to participate in the Diseases of Gastrointestinal Interoception Consortium (DGIC). The consortium seeks to identify mechanisms linking altered gastrointestinal interoception to dysmotility and symptoms, develop biomarkers for pathophysiology or treatment efficacy, and identify potential therapeutic targets for future clinical trials. Funding is provided through a cooperative agreement, with $4.5 million intended to support up to six awards. Applications are limited to $500,000 in direct costs per year, and project periods may not exceed five years.